HR 2227

Medical Gas Safety Act

Congress: 112 (2011–2013, Ended)
Chamber: House
Policy Area: Health
Introduced: Jun 16, 2011
Current Status: Referred to the Subcommittee on Health.
Latest Action: Referred to the Subcommittee on Health. (Jun 22, 2011)
Official Text: https://www.congress.gov/bill/112th-congress/house-bill/2227

Sponsor

Name: Rep. Lance, Leonard [R-NJ-7]
Party: Republican • **State:** NJ • **Chamber:** House

Cosponsors (10 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Murphy, Christopher [D-CT-5]	D · CT		Jun 16, 2011
Rep. Ross, Mike [D-AR-4]	D · AR		Jul 14, 2011
Rep. Barrow, John [D-GA-12]	D · GA		Nov 2, 2011
Rep. Engel, Eliot L. [D-NY-17]	D · NY		Nov 2, 2011
Rep. Matheson, Jim [D-UT-2]	D · UT		Nov 2, 2011
Rep. Sullivan, John [R-OK-1]	R · OK		Feb 1, 2012
Rep. Gingrey, Phil [R-GA-11]	R · GA		Mar 13, 2012
Rep. Guthrie, Brett [R-KY-2]	R · KY		Mar 13, 2012
Rep. Cassidy, Bill [R-LA-6]	R · LA		Mar 28, 2012
Rep. Chandler, Ben [D-KY-6]	D · KY		Apr 17, 2012

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Jun 22, 2011

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Summary (as of Jun 16, 2011)

Medical Gas Safety Act - Amends the Federal Food, Drug, and Cosmetic Act to set forth provisions regarding the regulation of medical gases, including to establish a certification and approval process for medical gases. Lists designated medical gases, including oxygen, nitrous oxide, and medical air. Requires the Secretary to: (1) approve a certification for designated medical gases; and (2) establish by rule appropriate procedures for the approval of medical gases that are not designated medical gases.

Requires the Secretary to establish regulations for medical gases, including: (1) appropriate current good manufacturing practice requirements, (2) separate labeling requirements, (3) separate wholesale distribution requirements, (4) a streamlined electronic process for registration and listing of medical gases, and (5) separate and proportionate product tracking and anti-counterfeiting rules for medical gases.

Requires the Secretary to establish: (1) a separate risk-based inspection regime specific to medical gas manufacturers that ensures coordination with state and local inspection activities, and (2) the Medical Gas Advisory Committee to provide the Secretary with regular guidance and specific advice on medical gas regulatory activities.

Directs the Secretary to assess and collect fees with respect to drugs that are non-designated medical gases, and establish the amount of fees to generate the total amount of costs of the Food and Drug Administration's (FDA's) regulation of non-designated medical gases. Exempts medical gases from new drug fees and new animal drug fees.

Actions Timeline

- **Jun 22, 2011:** Referred to the Subcommittee on Health.
- **Jun 16, 2011:** Introduced in House
- **Jun 16, 2011:** Referred to the House Committee on Energy and Commerce.